Traditional Chinese drugmakers prep to invade the West

The makers of traditional Chinese medicines are preparing for the world stage. The 7th World Congress of Chinese Medicine in Xinhua last week carried an unlikely theme that included such phrases as "clinical practice" and "scientific research."

Presentation titles did little to mask the ambitions of medicine makers. "Technical requirements for registration of Chinese medicine in the EU" and "Quality control of Chinese medicine" were among them.

And their efforts are hardly restricted to manufacturing topics: they are intent on proving the benefit of their treatments. Efforts are under way to create clinical trial protocols for traditional medicines that acknowledge their custom nature while meeting the proof standards of Western drug regulators.

- here's the article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.